Guadalupe Gomez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9217497/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Left-truncated Data With Age as Time Scale: An Alternative for Survival Analysis in the Elderly Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1998, 53A, M337-M343.	1.7	179
2	Survival Analysis Applied to Sensory Shelf Life of Foods. Journal of Food Science, 2003, 68, 359-362.	1.5	168
3	Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 560-565.	0.9	151
4	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	1.8	143
5	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. Aids, 2010, 24, 2827-2833.	1.0	140
6	Tutorial on methods for interval-censored data and their implementation in R. Statistical Modelling, 2009, 9, 259-297.	0.5	96
7	Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2008, 24, 1301-1307.	0.5	87
8	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. Aids, 2007, 21, 169-178.	1.0	74
9	Sensory shelf-life predictions by survival analysis accelerated storage models. Food Quality and Preference, 2006, 17, 468-473.	2.3	65
10	Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. European Journal of Cancer, 1994, 30, 785-792.	1.3	56
11	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Frontiers in Immunology, 2020, 11, 823.	2.2	55
12	Estimation of the Infection Time and Latency Distribution of AIDS with Doubly Censored Data. Biometrics, 1994, 50, 204.	0.8	50
13	Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 138-145.	0.6	46
14	Inference for a linear regression model with an interval-censored covariate. Statistics in Medicine, 2003, 22, 409-425.	0.8	44
15	Interval censoring: Model characterizations for the validity of the simplified likelihood. Canadian Journal of Statistics, 2004, 32, 315-326.	0.6	41
16	Frequentist and Bayesian approaches for interval-censored data. Statistical Papers, 2004, 45, 139-173.	0.7	41
17	Using the STROBE statement: survey findings emphasized the role of journals in enforcing reporting guidelines. Journal of Clinical Epidemiology, 2019, 116, 26-35.	2.4	36
18	Volcanic hazard assessment for the Canary Islands (Spain) using extreme value theory. Natural Hazards and Earth System Sciences, 2011, 11, 2741-2753.	1.5	34

GUADALUPE GOMEZ

#	Article	IF	CITATIONS
19	Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 796-805.	0.6	31
20	A cross-sectional bibliometric study showed suboptimal journal endorsement rates of STROBE and its extensions. Journal of Clinical Epidemiology, 2019, 107, 42-50.	2.4	31
21	Statistical considerations when using a composite endpoint for comparing treatment groups. Statistics in Medicine, 2013, 32, 719-738.	0.8	30
22	Bayesian survival analysis modeling applied to sensory shelf life of foods. Food Quality and Preference, 2006, 17, 307-312.	2.3	26
23	Non-parametric estimation with doubly censored data. Journal of Applied Statistics, 1999, 26, 45-58.	0.6	23
24	Informed Choice of Composite End Points in Cardiovascular Trials. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 170-178.	0.9	21
25	Bayesian joint ordinal and survival modeling for breast cancer risk assessment. Statistics in Medicine, 2016, 35, 5267-5282.	0.8	20
26	Residual analysis in linear regression models with an interval-censored covariate. Statistics in Medicine, 2004, 23, 3377-3391.	0.8	19
27	Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for <i>In Vivo</i> HIV Control. Journal of Virology, 2017, 91, .	1.5	18
28	A parametric survival model with an interval-censored covariate. Statistics in Medicine, 2004, 23, 3159-3175.	0.8	17
29	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	1.3	16
30	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. PLoS ONE, 2012, 7, e46031.	1.1	16
31	Interval censoring: identifiability and the constant-sum property. Biometrika, 2007, 94, 61-70.	1.3	15
32	Sensory cut-off point obtained from survival analysis statistics. Food Quality and Preference, 2015, 43, 135-140.	2.3	15
33	Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy. Antiviral Therapy, 2005, 10, 841-847.	0.6	15
34	Nonparametric Bayesian estimation from interval-censored data using Monte Carlo methods. Journal of Statistical Planning and Inference, 2001, 98, 73-87.	0.4	14
35	Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. Journal of NeuroVirology, 2010, 16, 208-218.	1.0	13
36	Risk of HIV infection as a function of the duration of intravenous drug use: a non-parametric Bayesian approach. Statistics in Medicine, 2000, 19, 2641-2656.	0.8	12

GUADALUPE GOMEZ

#	Article	IF	CITATIONS
37	The STROBE extensions: protocol for a qualitative assessment of content and a survey of endorsement. BMJ Open, 2017, 7, e019043.	0.8	12
38	Survival analysis model to estimate sensory shelf life with temperature and illumination as accelerating factors. Food Quality and Preference, 2018, 68, 371-376.	2.3	12
39	Estimation of the infection time and latency distribution of AIDS with doubly censored data. Biometrics, 1994, 50, 204-12.	0.8	12
40	A generalized Fleming and Harrington's class of tests for interval ensored data. Canadian Journal of Statistics, 2012, 40, 501-516.	0.6	11
41	Frequentist and Bayesian approaches for a joint model for prostate cancer risk and longitudinal prostate-specific antigen data. Journal of Applied Statistics, 2015, 42, 1223-1239.	0.6	11
42	Modeling the Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy. Mathematics, 2020, 8, 1631.	1.1	10
43	Survival Analysis For Left Censored Data. , 1992, , 269-288.		10
44	Estimation and residual analysis with R for a linear regression model with an interval ensored covariate. Biometrical Journal, 2014, 56, 867-885.	0.6	9
45	Estimating the Shelf Life of Brown Pan Bread, Suitability of Survival Analysis Methodology. Journal of Food Science, 2006, 71, S321-S325.	1.5	8
46	A dynamic model for the risk of bladder cancer progression. Statistics in Medicine, 2012, 31, 287-300.	0.8	7
47	The Use of a Binary Composite Endpoint and Sample Size Requirement: Influence of Endpoints Overlap. American Journal of Epidemiology, 2017, 185, 832-841.	1.6	7
48	Selection of composite binary endpoints in clinical trials. Biometrical Journal, 2018, 60, 246-261.	0.6	7
49	Selection of nature-based solutions to improve comfort in schools during heat waves. International Journal of Energy Production and Management, 2021, 6, 157-169.	1.9	7
50	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 2452-2459.	1.3	6
51	CD4+ lymphocytes and tuberculin skin test as survival predictors in pulmonary tuberculosis HIV-infected patients. International Journal of Epidemiology, 1998, 27, 703-712.	0.9	5
52	Decreased survival of patients with lung cancer admitted to a teaching hospital through the emergency department in Barcelona, Spain. Journal of Epidemiology and Community Health, 1998, 52, 137-138.	2.0	5
53	A SEMIPARAMETRIC HIERARCHICAL METHOD FOR A REGRESSION MODEL WITH AN INTERVAL-CENSORED COVARIATE. Australian and New Zealand Journal of Statistics, 2005, 47, 351-364.	0.4	5
54	Likelihood Maximization Using Web-Based Optimization Tools. American Statistician, 2005, 59, 192-202.	0.9	5

GUADALUPE GOMEZ

#	Article	IF	CITATIONS
55	Asymptotic properties of the left kaplan-meier estimator. Communications in Statistics - Theory and Methods, 1994, 23, 123-135.	0.6	4
56	Prenatal Exposure to Maternal Bereavement and Childbirths in the Offspring: A Population-Based Cohort Study. PLoS ONE, 2014, 9, e103353.	1.1	4
57	Multiple imputation approach for intervalâ€censored time to HIV RNA viral rebound within a mixed effects Cox model. Biometrical Journal, 2019, 61, 299-318.	0.6	4
58	Estimation and Asymptotic Properties of the Distribution of Tune-to-Tumour in Carcinogenesis Experiments. Mathematical Medicine and Biology, 1990, 7, 109-123.	0.8	3
59	Estimation of the subsurvival function for time-to-tumor in survival/sacrifice experiments. Statistics and Probability Letters, 1992, 13, 5-13.	0.4	3
60	Simultaneous marginal survival estimators when doubly censored data is present. Lifetime Data Analysis, 2011, 17, 347-372.	0.4	3
61	A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components. Statistics in Medicine, 2019, 38, 1935-1956.	0.8	3
62	Supervivencia en pacientes con tuberculosis infectados por VIH. Estudio de los fallecimientos en los primeros nueve meses. Revista Espanola De Salud Publica, 1999, 73, 549-562.	0.3	3
63	A Sampling-Based Chi-Squared Test for Interval-Censored Data. , 2008, , 295-306.		3
64	FARMS: A New Algorithm for Variable Selection. BioMed Research International, 2015, 2015, 1-11.	0.9	2
65	Selection of the primary end point in an observational cohort study. Journal of Epidemiology and Community Health, 2016, 70, 950-953.	2.0	2
66	Analyzing leftâ€truncated and rightâ€censored infectious disease cohort data with intervalâ€censored infection onset. Statistics in Medicine, 2021, 40, 287-298.	0.8	2
67	A Homogeneity Test for Follow-up Studies. Mathematical Medicine and Biology, 1988, 5, 101-112.	0.8	1
68	Comments on â€~Use of composite endpoints in clinical trials' by Abdul J. Sankoh, Haihong Li and Ralph B. D'Agostino, Sr. Statistics in Medicine, 2016, 35, 317-318.	0.8	1
69	Selecting the primary endpoint in a randomized clinical trial: The ARE method. Journal of Biopharmaceutical Statistics, 2016, 26, 880-898.	0.4	1
70	A nonparametric test for the association between longitudinal covariates and censored survival data. Biostatistics, 2020, 21, 727-742.	0.9	1
71	Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints. BMC Medical Research Methodology, 2021, 21, 99.	1.4	1
72	Correcting the bias due to dependent censoring of the survival estimator by conditioning. Statistics, 2014, 48, 295-314.	0.3	0

#	Article	IF	CITATIONS
73	Advanced Topics in Biostatistics: Editorial for the ISCB38 Special Issue. Biometrical Journal, 2019, 61, 243-244.	0.6	0
74	Design of phase III trials with longâ€ŧerm survival outcomes based on shortâ€ŧerm binary results. Statistics in Medicine, 2021, 40, 4122-4135.	0.8	0
75	A Multi-state Model for the Progression to Osteopenia and Osteoporosis Among HIV-Infected Patients. Trends in Mathematics, 2017, , 41-45.	0.1	0
76	An Ordinal Joint Model for Breast Cancer. Trends in Mathematics, 2017, , 9-13.	0.1	0
77	A class of two-sample nonparametric statistics for binary and time-to-event outcomes. Statistical Methods in Medical Research, 2022, 31, 225-239.	0.7	0
78	Description of survival with numerical and graphic indicators. Basics and mistakes to avoid. CirugÃa Española (English Edition), 2022, 100, 587-589.	0.1	0